Increased CD4+CD25+ regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients  by Shen, Chuan et al.
Journal of Microbiology, Immunology and Infection (2015) 48, 137e146Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEIncreased CD4DCD25D regulatory T cells
correlate with poor short-term outcomes in
hepatitis B virus-related acute-on-chronic
liver failure patientsChuan Shen a,d, Wen-Zhao Yan a,d, Cai-Yan Zhao a,*,
Hong-Hao Che a, Xiao-Yu Liu a, Zhen-Zhong Liu a,
Ya-Dong Wang a, Wei Wang a, Meng Li b, Jian Gao caDepartment of Infectious Disease, The Third Affiliated Hospital of Hebei Medical University,
Shijiazhuang, China
bDepartment of Endocrinology and Metabolism, The Third Affiliated Hospital of Hebei Medical
University, Shijiazhuang, China
cDepartment of Hepatobiliary Surgery, The Third Affiliated Hospital of Hebei Medical University,
Shijiazhuang, ChinaReceived 10 March 2013; received in revised form 15 October 2013; accepted 31 October 2013







Regulatory T cell* Corresponding author. Department
Shijiazhuang 050051, China.
E-mail address: zhaocy2005@163.c
d Chuan Shen and Wen-Zhao Yan con
1684-1182/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.jmii.2013Background: The roles of CD4þCD25þ regulatory T cells (Treg) in chronicity of hepatitis B virus
(HBV) infection have been confirmed. We aimed to explore alteration of Treg in patients with
HBV-related acute-on-chronic liver failure (ACLF).
Methods: Thirty-two HBV-related ACLF patients, 44 chronic hepatitis B patients, and 41
healthy controls were recruited. We detected frequencies of peripheral Treg and intrahepatic
forkhead winged helix transcription factor (Foxp3)þ cells. Inhibitory activity of Treg was as-
sessed by functional suppression assays. Serum interferon-g and interleukin-10 were also
determined.
Results: Peripheral Treg and intrahepatic Foxp3þ cells were more markedly increased in ACLF
than chronic hepatitis B and controls (all p < 0.001), and the Foxp3þ cells located predomi-
nantly in the portal areas. The Treg frequency was positively correlated with HBV DNA load,of Infectious Disease, The Third Affiliated Hospital of Hebei Medical University, 139 Ziqiang Road,
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138 C. Shen et al.international normalized ratio, model of end stage liver disease score, and serum interleukin-
10 level in ACLF patients. Functional assays in vitro demonstrated that ACLF patients exhib-
ited higher suppressive effects of Treg on proliferations of autologous CD4þCD25 T cells than
controls. On logistic regression, prolonged international normalized ratio and higher periph-
eral Treg frequency predicted 30-day survival of ACLF.
Conclusion: The patients with HBV-related ACLF exhibit increased amounts of Treg, of which
redistribution from periphery to liver seems to modulate liver inflammation. Higher Treg
amounts are associated with more severe liver disease in ACLF, and its level in combination
with international normalized ratio may assist prediction of short-term outcomes of HBV-
related ACLF.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Hepatitis B virus (HBV)-related acute-on-chronic liver fail-
ure (ACLF) refers to an acute deterioration of liver function
due to a precipitating event such as microbial infection,
reactivation of viral hepatitis, hepatotoxic drugs, surgical
procedures, or variceal bleeding occurring in patients with
any form of underlying chronic HBV infection.1,2 In China,
HBV infection constitutes >80% of all etiologies of ACLF
owing to a high carriage rate of HBV.3,4 HBV-related ACLF
exhibits relatively high mortalities and liver transplantation
is the most promising treatment.5,6
Recent studies have shed light on CD4þCD25þ regula-
tory T cells (Treg) that are actively engaged in the main-
tenance of immune tolerance to both self and nonself
antigens by suppressing aggressive T-cell response.7,8 This
specialized subpopulation of CD4þ T cells constitutively
expresses interleukin (IL)-2 receptor a-chain (CD25), and
represents approximately 2e4% of peripheral CD4þ T
cells.9 The forkhead-winged helix transcription factor
(Foxp3) has been demonstrated to be a unique molecule
for the development and functions of CD4þCD25þ
Treg.10,11
Accumulating evidence indicates that increased Treg
numbers are associated with persistence of HBV infection
by downregulating HBV-specific effector T cell
responses.12e15 Depletion of this proportion of cells in vitro
can enhance proliferation of effector cells and secretion of
interferon-g (IFN-g) against HBV antigens in a dose-
dependent manner.12,16 By contrast, the suppressive role
of Treg may prevent excessive immunopathological dam-
ages induced by sustained immune activation and inflam-
mation.17,18 ACLF often represents a complicated state of
host immune dysregulation, in which exacerbated innate
immune responses and aberrant adaptive immune re-
sponses may mediate hepatic inflammation.19e23 However,
it is still controversial whether Treg is increased or
decreased in HBV-related ACLF due to discrepant
results.16,24
In this study, we examined the frequency of peripheral
CD4þCD25þ Treg and the distribution of liver-infiltrating
Foxp3þ cells in patients with HBV-related ACLF. We
also investigated inhibitory functions of Treg, as well as
its association with short-term prognosis in HBV-related
ACLF.Patients and methods
Patients
A total of 32 patients with HBV-related ACLF and 44 with
chronic hepatitis B (CHB) were recruited at the Third
Affiliated Hospital of Hebei Medical University, Shi-
jiazhuang, China from September 2009 to December 2011.
Forty-one healthy individuals were selected as controls
matched for sex and age. The study protocol was approved
by the hospital Ethics Committee. Written informed con-
sent was obtained from the patients or their families prior
to enrollment. According to the Diagnostic and Treatment
Guidelines for Liver Failure issued by Chinese Society of
Hepatology and Chinese Society of Infectious Disease,25 the
inclusion criteria for HBV-related ACLF included: (1) car-
riage of hepatitis B surface antigen 6 months; (2)
detectable serum HBV DNA; (3) acute deterioration in liver
functions based on total bilirubin (TBIL)  171mM and pro-
thrombin activity 40%; and/or (4) recent development of
complications such as hepatic encephalopathy (HE), asci-
tes, spontaneous bacterial peritonitis, or hepatorenal syn-
drome. The definitions of CHB patients have been described
in detail elsewhere.16 Patients who had coinfection of
hepatitis A, C, E, or D viruses or human immunodeficiency
virus, autoimmune liver diseases, biliary obstruction, he-
molytic diseases, pregnancy, or malignancy were excluded.
No patient had received anti-HBV or immunosuppressive
agents 6 months prior to enrollment.
Samples
A blood sample was obtained from each participant at
enrollment. Tissue was collected from six explanted livers of
HBV-related ACLF, 23 biopsied livers from CHB, and six
healthy donors, respectively. One third of each specimenwas
stored in RNA fixer (GENEray Biotechnology, Shanghai, China)
at80 Cuntil RNAextractionwas conducted.The remainder
was fixed in 10% formalin for immunohistochemistry.
Laboratory tests
Serum albumin, alanine transaminase (ALT), aspartate
transaminase (AST), TBIL, and creatinine (CREA) were
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(AU2700, Olympus, Tokyo, Japan). Prothrombin time was
measured by Fully Automatic Coagulometer (Ac.T 5diff AL;
Beckman-Coulter Inc., Brea, CA, USA) for calculating its
derived parameters PTA and international normalized ratio
(INR). HBV serological markers including hepatitis B surface
antigen, anti-HBs, hepatitis B e antigen (HBeAg), anti-HBe,
and anti-hepatitis B core were determined by commercially
enzyme immunoassay kits (Yingkexinchuang Sci-Tech Co.,
Ltd., Xiamen, China). Serum HBV DNA load was quantified by
a real-time polymerase chain reaction (PCR) diagnostic kit
D.A. Gene, ZhongshanUniversity, Guangzhou, Chinawith the
lower limit threshold of 500 copies/mL. The model for end-
stage liver disease (MELD) score was calculated as follows:
3.78  Ln[TBIL (mg/dL)] þ 11.2  LnINR þ 9.57  Ln[CREA
(mg/dL)] þ 6.43  (constant for etiology: 0Z if cholestatic
or alcoholic, 1Z otherwise).
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated
from 2mL fresh heparinized blood by Ficoll-Hypaque (Sigma-
Aldrich, St Louis, MO, USA) density gradient centrifugation.
Then the isolated PBMCs were incubated with fluorescein
isothiocyanate-conjugated anti- CD4 and phycoerythrin-
conjugated anti-CD25 antibodies (eBioscience, San Diego,
CA, USA) at room temperature for 20minutes. After staining,
the cells were washed twice with phosphate-buffered saline
(PBS), and then fixed in 1% paraformaldehyde. The stained
cells were subsequently processed on an EPICS-XL FCM
(Beckman-Coulter) for analysis, and CD4þCD25þ Treg cells
were gated within the lymphocyte population. Isotype-
matched control antibodies were used to separate positive
and negative cells on FITC and PE fluorescence channels. All
data were analyzed by (Beckman-Coulter).
Quantitative real-time PCR
Total RNA was extracted from the PBMCs and liver tissues
using Redzol reagent (Saibaisheng-SBS, Beijing, China) ac-
cording to the manufacturer’s protocol. The extracted RNA
was reverse transcribed to first strand cDNA using the Pri-
meScript RT reagent Kit (Fermentas, Burlington, ON, Can-
ada). Quantification of gene expressions were carried out in
a thermal cycler (ABI 7500; Applied Biosystems, Foster City,
CA, USA) using a SYBR-green RealMaster Mix kit (TianGen
Biotech, Beijing, China). The amplification programs were
an initial 94 C for 5 minutes, followed by 35 cycles at 94 C
for 30 seconds, 58 C for 30 seconds, and 72 C for 1 minute.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control. The sequences of primers were:
Foxp3: forward: 50-CCTCCCCCATCATATCCTTT-30 and
reverse: 50-TTGGGGTTTGTGTTGAGTGA-30 (size: 236 bp);
and GAPDH: forward: 50-ACCACAGTCCATGCCATCACT-30 and
reverse: 50-TCCACCACCCTGTTGCTGTA-30 (size: 452 bp). For
each sample, PCR was performed twice in triplicates, and
all data were analyzed by the thermal cycler’s software to
calculate the DCt value (DCtZ Ct value of the target gene
minus Ct value of the internal control gene). Relative
expression of Foxp3 to the internal control was calculated
using the 2DDCt method.26Immunohistochemistry
Paraffin-embedded, 10% formalin fixed liver tissues were
sectioned in 5 mm. Antigen retrieval was achieved via pres-
sure cooking for 8 minutes in citrate buffer (PH 6.0). After
blocking the endogenous peroxidase activitywith 3%H2O2, all
sectionswere incubatedwithmonoclonal antibody ofmouse-
anti-human Foxp3 (1:80 dilution; Abcam, Cambridge, UK)
overnight at 4C. Two-Step immunohistochemistry Detection
Reagent (Zhongshan Golden Bridge Biotech, Beijing, China)
containing secondary rabbit anti-mouse antibody, and 3,30-
diaminobenzidine tetrahydrochloride Substrate Kit (Zhong-
shan Golden Bridge Biotech) were further applied for detec-
tion according to manufacturer’s protocols. The Foxp3þ cells
were enumerated in three high-powered (400) fields (hpf)
by two independent observers. The average percentage of
positive cells was taken for each specimen.
Enzyme-linked immunosorbent assay
Serum IFN-g and IL-10 were measured using commercially
available enzyme-linked immunosorbent assay kits (Rap-
idbio, West Hills, CA, USA) according to the manufacturer’s
instructions. All samples were analyzed in duplicate.
CD4DCD25D Treg isolation
CD4þCD25þ Treg were isolated from fresh PBMCs by CD4-
negative selection, followed by CD25-positive selection,
using MACS microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. The
reminder population was CD4þCD25 T cells, which were
regarded as responder cells. The purity of two-cell sub-
populations, determined by flow cytometry, exceeded 90%
for CD4þCD25þ Treg and 85% for CD4þCD25 T cells.
Inhibitory function assay
The isolated CD4þCD25 Tcells (2.0 105/well) were seeded
into 96-well plates, and then stimulated with 1 mg/mL of
plate-bound anti-CD3 antibody (eBioscience) and 1 mg/mL of
anti-CD28 antibody (eBioscience) in RPMI 1640 medium
containing 10% FCS. Autologous CD4þCD25þ Tregwere added
to CD4þCD25 T cells at ratios of 1:1, 1:2, and 1:5. Control
cultures were performed using CD4þCD25 T cells instead of
CD4þCD25þ Treg under identical conditions. The cells were
co-cultured in triplicate and incubated for 72 hours at 37C
with 5% CO2. Eighteen hours prior to the end of culture,
0.5 mCi/well of 3H-thymidine was added. The amount of
incorporated 3H-thymidine was determined by liquid scin-
tillation spectroscopy. Percentage inhibition was calculated
as 1 e (counts/minute in the presence of CD4þCD25þ Treg/
counts/minute in the absence of CD4þCD25þ Treg)  100%.
Statistical analysis
All data were analyzed by SPSS software version 17.0 (SPSS
Inc., Chicago, IL, USA). Continuous variables are expressed
as mean  standard deviation. Normally distributed data
were analyzed using one-way ANOVA, followed by
Table 1 Clinical and biochemical characteristics of all participants
HBV-related ACLF (n Z 32) Chronic hepatitis B (n Z 44) Controls (n Z 44)
Age 45  12 37  13 39  16
Sex (male/female) 25/7 29/15 26/15
Albumin (g/L) 31.1  4.4*,** 41.4  6.3*** 43.9  3.2
ALT (U/L) 309  331** 171  134*** 19  11
AST (U/L) 325  348*,** 108  78*** 20  7
TBIL (mM) 407.0  145.4*,** 28.6  55.3*** 11.3  4.0
DBIL (mM) 218.3  70.5*,** 12.1  32.4*** 2.2  1.0
CREA (mM) 102.8  42.4*,** 69.6  10.6 68.6  12.8
PTA (%) 27.6  7.7*,** 102.2  17.4 107.7  12.4
INR 2.6  0.8*,** 1.1  0.1*** 1.0  0.1
HBeAg (þ)/HBeAg () 15/17 25/19 0/0
HBV DNA level (log10 copies/mL) 5.3  1.4 5.8  1.2 ND
Severe complications 19 (59.4)*,** 0 (0) 0 (0)
HE 9 (28.1)*,** 0 (0) 0 (0)
SBP 11 (34.4)*,** 0 (0) 0 (0)
HRS 5 (15.6)*,** 0 (0) 0 (0)
VB 2 (6.3)*,** 0 (0) 0 (0)
30-day mortality 17 (53.1)*,**,a 0 (0) 0 (0)
a One patient who received liver transplantation within the 30-day observation was arbitrarily assigned to the nonsurvivor group.
Data are presented as n (%) or mean  SD, unless otherwise indicated.
*p < 0.01 versus CHB.
**p < 0.01 versus healthy controls.
***p < 0.01 versus healthy controls.
ACLF Z acute-on-chronic liver failure; HBeAg Z hepatitis B e antigen; ALT Z alanine transaminase; AST Z aspartate transaminase;
TBIL Z total bilirubin; DBILZ direct bilirubin; CREAZ creatinine; PTA Z prothrombin activity; INRZ international normalized ratio;
HBV Z hepatitis B virus; HE Z hepatic encephalopathy; HRS Z hepatorenal syndrome; ND Z not done; SBP Z spontaneous bacterial
peritonitis; VB Z variceal bleeding.
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cording to the tests of homogeneity of variances. For non-
normally distributed data, differences between groups
were analyzed using nonparametric KruskaleWallis H test,
followed by ManneWhitney U test for multiple compari-
sons. Pearson Chi-square test or Fisher’s exact test was
used to analyze categorical variables as appropriate.
Bivariate correlation analysis was assessed by Spearman
correlation test. All statistical tests were two-tailed, and
p < 0.05 was considered to be statistically significant.
Logistic regression analysis with forward stepwise vari-
ables selection was used to demonstrate the independent
predictors for 30-day mortality of patients with HBV-related
ACLF. The covariates included age, sex, HBeAg status, HBV
DNA loads, ALT, AST, TBIL, CREA, INR, peripheral Treg fre-
quency, and serum IL-10 level.Results
Demographic and clinical characteristics
The demographic and clinical characteristics of patients
with HBV-related ACLF, patients with CHB, and healthy
controls are summarized in Table 1. There were no signifi-
cant differences in HBV DNA loads and ratios of HBeAg
positive/HBeAg negative between ACLF patients and CHB
patients. Of all ACLF patients, 19 (59.4%) exhibited severe
complications, including nine with HE, 11 with spontaneous
bacterial peritonitis, five with hepatorenal syndrome, and
two with variceal bleeding.Peripheral CD4DCD25D Treg frequency
As shown in Fig. 1, ACLF patients had a significantly higher
frequency of peripheral Treg (6.33%  1.49%; median
6.21%) than CHB patients (4.16%  1.31%; 3.85%; p < 0.001)
and healthy controls (2.20%  0.69%; 2.33%; p < 0.001).
There is also a significant difference between CHB patients
and healthy controls (p < 0.001). In addition, ACLF patients
with severe complications (6.51%  1.50%; 6.74%) displayed
higher levels of circulating Treg than patients without any
complications (5.94%  1.42%; 5.91%), but there was no
significance (p Z 0.552).
Hepatic Foxp3D cells frequency
The highest mean frequency of Foxp3þ cells was detected
in livers from ACLF patients (14.7  3.6/hpf; 14/hpf)
compared with CHB patients (4.6  1.4/hpf; 5.0/hpf;
p < 0.001) and healthy controls (0.4  0.2/hpf; 1/hpf;
p < 0.001). More Foxp3þ cells were also observed in CHB
patients than healthy controls (p < 0.001). The distribution
of Foxp3þ cells were predominantly in portal areas, and
occasionally scattered in hepatic sinusoids (Fig. 2).
Foxp3 mRNA expression
The level of Foxp3 mRNA in healthy controls was assigned as
a reference value of 1. The Foxp3 mRNA levels in both
PBMCs and livers were significantly upregulated in ACLF
patients (PBMCs: n Z 13; 8.09  1.34 and livers: n Z 6;
Figure 1. Comparison of peripheral percentages of CD4þCD25þ regulatory T cells (Treg) within total CD4þ T cells among patients
with acute-on-chronic liver failure (ACLF), patients with chronic hepatitis B (CHB), and healthy controls. (A) Representative dot
plots obtained by flow cytometry using antibodies against both CD4 and CD25 molecules. (B) Frequencies of CD4þCD25þ Treg in the
above three groups. Data are expressed as box plots, in which the horizontal lines illustrate the 25th percentile, 50th percentile, and
75th percentile, whereas the vertical lines represent the 10th percentile and 90th percentiles. *p < 0.001 versus CHB, **p < 0.001
versus healthy controls.
Treg and HBV-related ACLF 1415.89  2.06) than CHB patients (PBMCs: nZ 15; 3.33  1.06
and livers: n Z 13; 2.12  0.25; all p < 0.001) and healthy
controls (PBMCs: n Z 10 and livers: n Z 6; all p < 0.001;
Fig. 3).Inhibitory activity of CD4DCD25D Treg
The suppressive ability of CD4þCD25þ Treg on proliferation
of the responder cells (CD4þCD25 T cells) was investigated
in six ACLF patients, 10 CHB patients, and eight healthy
controls. The CD4þCD25 T cells exhibited strong prolifer-
ation upon anti-CD3/anti-CD28 stimulations in the absence
of Treg. Reconstitution of Treg could significantly inhibit
proliferation of autologous responder cells in a dose-
dependent manner. The inhibitory degrees according to
different ratios of CD4þCD25 T cells to CD4þCD25þ Treg
(1:1, 1:2, and 1:5) were 61.27%  9.72%, 49.51%  8.18%,
and 25.52%  5.34% for ACLF, 53.62%  7.74%,
46.33%  7.37%, and 23.34%  5.50% for CHB,
35.71%  5.40%, 27.30%  6.35%, and 18.10%  3.59% for
healthy controls, respectively (all p < 0.05 when ACLF vs.
controls and CHB vs. controls). Although Treg isolated from
both ACLF and CHB patients exhibited increased suppres-
sive activity toward responder cells than healthy controls,no significant difference of inhibitory percentage was
observed between ACLF and CHB patients (Fig. 4).
Peripheral Treg and disease severity
In ACLF patients, there was a positive correlation between
circulating Treg and serum HBV DNA loads (r Z 0.36,
p Z 0.046; Fig. 5A). However, no correlation was found
between circulating Treg and HBeAg status, even though
four HBeAg negative patients who showed precore/core
promotor mutations had been excluded. There were no
correlations between Treg frequency and serum ALT, AST,
TBIL, and CREA; whereas it was positively correlated with
INR (r Z 0.64, p < 0.001, Fig. 5B) and the MELD score
(r Z 0.37, p Z 0.042, Fig. 5C).
Th1/Th2 shift and peripheral Treg
Serum IFN-g level in ACLF patients (0.96  0.37 pg/mL) was
significantly elevated than CHB patients (0.40  0.17 pg/
mL, p < 0.001) and healthy controls (0.37  0.17 pg/mL,
p < 0.001). Our study also revealed that serum IL-10 was
significantly increased in ACLF patients (0.77  0.33 pg/mL)
compared with CHB patients (0.48  0.27 pg/mL,
Figure 2. Immunohistochemistry of forkhead winged helix transcription factor (Foxp3) in livers. Foxp3þ cells localized mainly in
the inflammatory areas or occasionally scattered in hepatic sinusoids. (AeC) Representative graphs of hepatic expression and
distribution of Foxp3 in patients with acute-on-chronic liver failure (ACLF), patients with chronic hepatitis B (CHB), and healthy
controls. (D) Comparison of the amounts of Foxp3þ cells among above three groups. Data are expressed as median, 25th percentile,
and 75th percentile. * p < 0.001 versus chronic hepatitis B, ** p < 0.001 versus healthy controls (original magnification: 400).
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p < 0.001), and its level in ACLF patients was correlated
with peripheral Treg frequency (r Z 0.41, p Z 0.025,
Fig. 5D). Moreover, there was a higher ratio of IFN-g/IL-10
in ACLF patients (1.49  0.83) as compared with CHB pa-
tients (1.25  1.08; p Z 0.037) and healthy controls
(0.98  0.63; p Z 0.004).Figure 3. Comparisons of relative forkhead winged helix
transcription factor (Foxp3) mRNA expressions in both periph-
eral blood mononuclear cells (PBMCs) and livers among pa-
tients with acute-on-chronic liver failure (ACLF), patients with
chronic hepatitis B (CHB), and healthy controls. * p < 0.01
versus CHB, ** p < 0.01 versus healthy controls.Peripheral Treg correlates with poor short-term
prognosis
We investigated the kinetics of peripheral Treg in 26 ACLF
patients who had received only standard medical treatment
except liver transplantation by determination of theirFigure 4. Comparisons of suppressive activity of CD4þCD25þ
Treg on proliferation of autologous CD4þCD25 T cells among
acute-on-chronic liver failure (ACLF) patients, chronic hepati-
tis B (CHB) patients and healthy controls when CD4þCD25 T
cells and CD4þCD25þ Treg cocultured at various ratios of 1:1,
2:1, and 5:1. ** p < 0.05 versus healthy controls at the same
ratio of CD4þCD25þ Treg to CD4þCD25 T cells.
Figure 5. Significant correlations were found between circulating frequencies of CD4þCD25þ Treg and Log10 (A) hepatitis B virus
(HBV) DNA, (B) international normalized ratio, (C) model for end-stage liver disease (MELD) score, and (D) serum level of inter-
leukin-10 international normalized ratio (INR), model for end-stage liver disease (MELD) score, and serum level of interleukin-10 in
patients with HBV-related acute-on-chronic liver failure.
Table 2 The baseline data of survivors and nonsurvivors
with hepatitis B virus-related acute-on-chronic liver failure





Age 44  15 43  10
Sex (male/female) 10/0 12/4
Albumin (g/L) 32.1  4.8 30.9  4.5
ALT (U/L) 346  455 297  277
AST (U/L) 212  155 501  526
TBIL (mM 336.8  153.4 430.8  119.0
DBIL (mM) 187.5  72.8 234.2  65.3
CREA (mM) 87.9  39.7 99.5  38.3
INR 1.9  0.2 2.8  0.7*
HBeAg (þ)/HBeAg () 3/7 7/9
HBV DNA level
(log10 copies/mL)
4.6  1.1 5.4  1.5
IFN-g 0.939  0.439 0.995  0.361
IL-10 0.579  0.316 0.900  0.292**
Data are presented as mean  SD.
*p < 0.01.
**p < 0.05.
ALT Z alanine transaminase; AST Z aspartate transaminase;
TBILZ total bilirubin; DBILZdirect bilirubin; CREAZ creatinine;
INR Z international normalized ratio; IFN-g Z interferon-g; IL-
10 Z interleukin 10; HBeAg Z hepatitis B e antigen;
HBVZ hepatitis B virus.
Treg and HBV-related ACLF 143frequencies every 7 days. According to the outcomes after
30-day observation, these patients were divided arbitrarily
into the survival group (n Z 10) and the nonsurvival group
(n Z 16). Table 2 describes the baseline characteristics of
the above two groups. As shown in Fig. 6, the nonsurvivors
(6.68%  1.32%) had a higher baseline Treg frequency
compared with the survivors (5.44%  1.18%, p Z 0.024),
and showed an increasing trend with mean levels of
7.23%  1.34%, 7.79%  1.20%, 8.82%  0.91%, and
8.91%  0.18% on Day 7, Day 14, Day 21, and Day 28,
respectively. By contrast, the survival group presented as a
decline with levels of peripheral Treg of 5.53%  1.28%,
5.28%  1.03%, 4.45%  0.87%, and 3.47%  0.61% at each
time point (all p < 0.001 nonsurvivors vs. survivors).
Furthermore, logistic regression analysis demonstrated that
higher INR (odds ratio 5.9; 95% confidence interval
1.6e24.0; p Z 0.026) and increased peripheral Treg fre-
quency (odds ratio 3.9; 95% confidence interval 1.4e10.9;
p Z 0.042) can be used to predict 30-day survival of HBV-
related ACLF.
Discussion
HBV infection remains a serious public health problem,
worldwide affecting 350e400 million people.27 A small
proportion of patients with chronic HBV infection may
develop ACLF which exhibits high mortalities and poor
prognosis. Although pathogenesis of HBV-related ACLF is
extremely complex and still remains unclear, dysregulation
Figure 6. Kinetics of peripheral CD4þCD25þ Treg in patients
with hepatitis B virus (HBV)-related acute-on-chronic liver
failure (ACLF) receiving standard medical treatment for 30
days. Peripheral CD4þCD25þ Treg remain at high levels in the
nonsurvival group, whereas the survival group displays a
gradual decline. The circles and the error bars represent means
and standard deviations. * p < 0.01 versus the survival group at
each time-point; ** no comparison between two groups due to
insufficient sample sizes.
144 C. Shen et al.of host immune responses induced by host-HBV interactions
is proposed to be the most contributing factor.28,29 It has
been suggested that Treg may play a crucial role in con-
trolling immunopathological damage, but it may also
contribute to hyporesponsiveness against infection.
The relationship between Treg and HBV-related ACLF is
poorly understood. We observed that ACLF patients had a
markedly higher peripheral CD4þCD25þ Treg, as well as
increased inhibitory activity against CD4þCD25 responder
cells, than healthy controls. Our data are identical to those
observed by Xu et al,16 who showed that patients with
chronic severe hepatitis B (i.e., HBV-related ACLF) had the
highest circulating CD4þCD25high Treg among patients with
different phases of HBV infections. These results support
the notion that upregulation of Treg in ACLF may suppress
immune responses, thereby limiting liver injuries and
inflammation caused by necrosis or apoptosis of hepato-
cytes. However, Wang et al24 demonstrated the opposite
finding that decreased peripheral CD4þCD25þCD127low Treg
could aggravate liver injuries by enhancing immunological
responsiveness to HBV in HBV-related ACLF. The discrep-
ancies between these studies may be largely attributed to
differences in the molecular markers selected for identi-
fying Treg. Previous studies have confirmed that early-stage
ACLF are usually characterized by immune activation, but
“sepsis-like” immune paralysis usually accompanies late-
stage ACLF.19,30 Thus, we propose that host immune sta-
tus in different phases of ACLF may also be responsible for
numbers and functions of Treg. Although higher Treg were
observed in patients with severe complications with no
statistical significance, a larger sample size may lead to a
statistical significance.
The Treg cells, much like effector T cells, can accumu-
late and migrate into the sites of infection or inflammation,
where they deal directly with the activated T cells and
exert their effects against immune pathology.31e34 Liver
can rapidly mobilize and/or recruit Foxp3þCD4þ Treg withsuppressive activity in response to intrahepatic appearance
of activated CD8þ cells,35 which have been shown to be
increased in livers of patients with HBV-related ACLF.16,20
Because liver is the principle organ affected by HBV
infection, we investigated the profile of hepatic Foxp3þ
cells in HBV-related ACLF. Our immunohistochemistry study
showed profound accumulations of Foxp3þ cells in livers of
HBV-related ACLF patients, and this cell population local-
ized predominantly in lymphocyte-rich or inflamed areas,
whereas normal liver did not comprise such striking cell
population, indicating their direct role in the regulation of
local immunity and injuries.
Interestingly, we did not find any correlation between
circulating Treg and serum ALT, which reflects the degree
of liver inflammation. However, a positive correlation was
observed between peripheral Treg and INR. We firstly
demonstrated that increased Treg had a correlation with
the MELD score, which is recommended as a prognostic
score for ACLF.2 The above results suggest that increased
Treg may be a predictive value for the severity of ACLF.
The shift of Th1/Th2 response presenting as profoundly
imbalanced ratio of IFN-g/IL-10 has been observed in our
study. IFN-g is postulated to be a principle proinflammatory
cytokine involved in stimulating hepatic inflammation and
aggravating liver damage.36 High level of intrahepatic IFN-g
was associated with severe liver damage in human ACLF.20
Thus, substantially increased Treg may be a protective fac-
tor for immune homeostasis by antagonizing enhanced pro-
duction and effects of IFN-g. We have also observed a
compensatory increase in serum anti-inflammatory cytoki-
neeIL-10 in ACLF patients, and the IL-10 level was positively
correlatedwithperipheral Treg. It has been reported that one
potential mechanism that CD4þCD25þ Treg control immune
responses is due to IL-10, by which the peripheral conversion
of CD4þCD25 T cells to CD4þCD25þ Treg is also promoted.
Our study also explored the kinetics of peripheral Treg
and their relationship with short-term prognosis in HBV-
related ACLF. The results demonstrate that early lower
level and a decline trend of Treg seem to be followed by a
likelihood of better short-term prognosis. A possible
mechanism may be that when a patient’s condition has
been improved, activated Treg may undergo death through
an activation-induced cell death pathway.37 Moreover,
migration of peripheral Treg into the inflamed liver may
also account for the restoration of peripheral Treg to
normal range. By contrast, strikingly high levels of periph-
eral Treg were persistent in nonsurvivors, suggesting that
liver inflammation may not be regulated by intra-
hepaticeperipheral redistribution of Treg due to severe
immune dysmodulation. In addition, some molecules
increased in ACLF such as lipopolysaccharide, pathogen
associated molecular patterns, and inflammatory tissue
factors may be capable of favoring production and function
of Treg.7 Because both ACLF patients and CHB patients had
similar inhibitory functions of peripheral Treg, it is also
likely that partial proportion of increased Treg in ACLF may
have substantially functional deficiencies that could not
exert their physiological properties.
In conclusion, patients with HBV-related ACLF exhibit
increased circulating CD4þCD25þ Treg and intrahepatic
Foxp3þ cells, of which redistribution from periphery to liver
seems tomodulate local inflammation. Persistent high levels
Treg and HBV-related ACLF 145of peripheral Treg are not only associatedwith amore severe
degree of liver disease, but are also likely to assist in the
prediction of short-term outcomes of HBV-related ACLF.
With potentially anti-inflammatory functions, immune-
modulation treatment targeting Treg may provide potential
strategies for the interventions of HBV-related ACLF.Conflicts of interest
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